Most recent update: Friday, April 3, 2020 - 08:40

Bariatric News - Cookies & privacy policy

You are here

EndoBarrier Gastrointestinal Liner


Europe, Australia


EndoBarrier Therapy is new approach that does not rely on medication or involve surgery to help patients regain control of type 2 diabetes. The EndoBarrier medical device is placed in the intestine through a small tube that is inserted through the mouth, mimicking the effects of gastric bypass , without the risks associated with surgery. There are no incisions or scars. The procedure usually takes less than 30 minutes and patients can go home immediately.

EndoBarrier acts as a physical barrier between food and that part of the intestine wall where the medical device is present. This action delays digestion and intervenes with the body’s metabolic functions, which results in improved diabetes control and weight loss.

The EndoBarrier medical device may be implanted for up to 12 months of use and has shown benefits in three-month, six-month and 12-month studies. According to the company, the device is easily removed, also endoscopically, during a simple, outpatient procedure, and initial studies have demonstrated that EndoBarrier®= Therapy has sustained benefits on glycemic control and weight loss post-explant.

EndoBarrier is not approved for sale in the United States and is considered investigational. EndoBarrier has CE mark approval in Europe as well as TGA approval in Australia, and is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.